Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity

Area of Science:

• Computational biology
• Pharmacogenomics
• Bioinformatics

Background:

• Network-based computational methods are advancing drug development, including drug repositioning.
• MicroRNAs (miRNAs) are crucial in biological processes and can be targeted by drugs.
• Existing methods lack tissue specificity in predicting drug-disease relationships based on miRNA data.

Purpose of the Study:

• To propose a novel method, miTS, for predicting potential drug-disease associations by integrating miRNA data and tissue specificity.
• To identify new therapeutic uses for existing drugs through computational analysis.

Main Methods:

• Constructed a tissue-specific protein-protein interaction (PPI) network using miRNA and drug target data.
• Built a tripartite network model: drug-miRNA-disease.
• Evaluated drug-disease associations based on the tripartite network.

Main Results:

• The miTS method predicted potential treatments for diseases, with a case study on breast cancer.
• Out of the top 30 predicted drugs for breast cancer, 83.3% had known associations, and 5 were newly identified.
• Newly predicted drugs, like Regorafenib, showed strong evidence through pathway analysis and literature mining.

Conclusions:

• The miTS method is effective and practical for predicting new drug indications.
• This approach offers significant potential for discovering treatments for complex diseases.
• Regorafenib shows promise as a potential new treatment for breast cancer, warranting further investigation.